emraclidine
emraclidine: developed by 1 company · 3 clinical trials tracked.
emraclidine evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could emraclidine → CERE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cerevel Therapeutics Holdings, Inc. (CERE) | Phase 2 |
Clinical Trials (3)
A Phase 1, Open-label, Single Dose, Crossover Study to Assess the Relative Bioavailability of Emraclidine Formulations in Healthy Adult Subjects
Primary endpoint: Number of Participants with Adverse Events (AEs)
An Adaptive Two-part Randomized, Double Blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Emraclidine in Participants With Schizophrenia
Primary endpoint: Number of Participants with Adverse Events (AEs)
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Frequently asked questions
Who is developing emraclidine?
emraclidine is being developed by Cerevel Therapeutics Holdings, Inc..
How many clinical trials involve emraclidine?
BioSniper tracks 3 clinical trials involving emraclidine.